UPDATED: Instructions for Healthcare Providers of U.S. Citizens from Diamond Princess Who Have Tested Positive for COVID-19 in Japan

U.S. Centers for Disease Control and Prevention (CDC) Criteria for Return Travel to the U.S.

February 27, 2020

Dear U.S. citizen from the Diamond Princess cruise ship,

CDC has updated its guidance for lifting Do Not Board (DNB) travel restrictions related to U.S. Citizens from Diamond Princess who have tested positive for COVID-19 in Japan. If you previously tested positive for coronavirus (COVID-19), you received a letter on February 20, 2020, with guidance about how to become eligible to board a U.S.-bound flight:

1. Resolution of fever, without use of fever-reducing medication,
2. Improvement of illness symptoms, and
3. Two negative sets of test results from both a nasal swab and a throat swab taken at least 24 hours apart.

This CDC-established criterion is still the preferred method of testing. However, if you have difficulty obtaining the CDC-recommended testing, you can now follow testing guidance from the Japanese Ministry of Health, Labour and Welfare but you must also meet all of the following criteria:

1. Resolution of fever without the use of fever-reducing medication;
2. Improvement of illness symptoms;
3. Certified completion of Japanese testing criteria (i.e., negative results from at least two swabs collected at least 12 hours apart). This is the standard testing protocol used in Japanese hospitals for Japanese patients;
4. At least five days have passed since your second negative test result;
5. At least 15 days have passed since your first positive test result; and,
6. The absence of a productive cough.

Meeting all 6 of the requirements above will allow you to be removed from the DNB list.

Once you have completed your testing and received your test results, please confirm with the Japanese medical provider that all your test results were submitted to the U.S. Centers for Disease Control and Prevention representative at U.S. Embassy Tokyo by email TokyoCoronavirusCDC@state.gov (preferred), or FAX 03-3224-5886.